PDCD1 and diffuse large B-cell lymphoma: Interestingly, cHL clustering at the advanced stage of immune escape reveals that cHL are not immune deserts, but rather highly immunogenic tumors, accounting for their high rates of therapeutic responses to PD-1-blockade, most notably when compared to DLBCL.